title: New developments in the management of borderline resectable pancreatic cancer.
abstract: The optimal management of borderline resectable pancreatic cancer remains unclear. Neoadjuvant chemoradiation remains the most common approach in the United States, while neoadjuvant chemotherapy alone is also widely utilized and has demonstrated efficacy but there has been no clear consensus about a regimen that would be most beneficial in this setting. We will discuss three abstracts that were presented in the 2013 ASCO Gastrointestinal Cancers Symposium in which various regimens were evaluated in the neoadjuvant setting.
authors.affiliation: Division of Hematology Oncology, Department of Medicine, Tufts Medical Center, Boston, MA 02111, USA. jsharma@tuftsmedicalcenter.org
authors.forename: Jaya
authors.initials: J
authors.lastname: Sharma
authors.forename: John
authors.initials: J
authors.lastname: Ng
authors.forename: Martin D
authors.initials: MD
authors.lastname: Goodman
authors.forename: Muhammad Wasif
authors.initials: MW
authors.lastname: Saif
mesh_terms: D000230:Adenocarcinoma / Q000473:pathology* / Q000601:surgery / Q000628:therapy*; D059248:Chemoradiotherapy / Q000379:methods; D006801:Humans; D020360:Neoadjuvant Therapy / Q000379:methods; D009361:Neoplasm Invasiveness; D009367:Neoplasm Staging; D010180:Pancreatectomy; D010190:Pancreatic Neoplasms / Q000473:pathology* / Q000601:surgery / Q000628:therapy*